Introduction
Bladder cancer is common worldwide, with an estimated global incidence of > 356 000 new cases each year and a prevalence of 2.7 million cases. 1, 2 The morbidity of bladder cancer will increase in the foreseeable future, due to changes in exposure to risk factors for bladder cancer development, as well as growth and ageing of the global population. 1, 2 Of newly diagnosed bladder cancer cases, > 90% are transitional cell carcinomas (TCC), approximately 70 -80% are non-muscle invasive tumours (pT a -pT 1 ) and the remainder are muscle invasive tumours (pT 2 -pT 4 ). 3 Between 50% and 70% of non-muscle invasive tumours will relapse and 10 -30% will progress to become muscle invasive tumours. 3 
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For patients with bladder cancer of all stages, the 5-year survival rate is approximately 80%, 4, 5 and for non-muscle invasive disease, the 5-year survival rate is about 90%. 4, 5 For patients with pT 2 disease the 5-year survival rate is approximately 60%, whereas for patients with pT 3 disease this rate decreases to 35%. Finally, for pT 4 disease the survival rate is approximately 25%. 5 -7 Survival rate is decreased with tumour progression. 8 As tumours with similar morphology behave differently, it is of critical concern to identify accurately which tumours will progress after initial therapy and, therefore, which patients will require aggressive post-operative additional systemic therapy. 3 Thus, in addition to common clinicopathological features, biomarkers are needed to identify accurately which tumours possess malignant tendencies, especially those that correlate with the malignant behaviour of bladder TCC.
H-cadherin (CDH13; also known as Tcadherin) is a member of the cadherin family. Cadherins are a superfamily of calcium-dependent intercellular adhesion molecules that play a key role in cell-cell adhesion and are also involved in contact inhibition of cell growth by inducing cellcycle arrest. 9 Due to the down-regulation of cadherin, changes in cell-cell and cellmatrix adhesion accompany the transition from a benign to an invasive malignant tumour, as well as the subsequent metastatic dissemination of tumour cells. 10 CDH13 has been considered to be a tumour suppressor; the introduction of CDH13 in human tumour cells can reduce their invasive potential and decrease their proliferation significantly. 11 -14 In addition, CDH13 can induce the reversion of morphology from an invasive to a normal cell-like type. 11 -14 The human CDH13 gene is located on chromosome 16q24 and is frequently silenced in human cancers by promoter methylation. 12 DNA methylation is an enzyme-induced chemical modification that principally concerns the cytosine molecule, on which a methyl residue is transferred at the 5′ position. This modification mainly occurs in cytosineguanine dinucleotide-rich areas, known as CpG islands, in the gene promoter regions. 15 In humans, CpG islands associated with promoters are normally unmethylated, with some exceptions (namely, tissue-specific genes, imprinted genes and genes located on the inactive X chromosome in females), and the methylation of a CpG island linked to a promoter invariably correlates with silencing of the gene. 16 Promoter methylation is the most common and bestcharacterized epigenetic change in human malignancies. DNA methylation of the promoter regions is a major mechanism of inactivation of tumour suppressor genes and can act as a substitute to gene deletion or mutation. 15 Detection of DNA promoter methylation in cancers may be used as a diagnostic, prognostic or surveillance biomarker, especially when the aberrant methylation inactivates tumour suppressor genes. 17, 18 The methylation of the promoter region of the CDH13 gene has been reported in several human cancers, including bladder cancer, 12 but the methylation status of CDH13 in serum DNA and its clinical significance for patients with bladder TCC remain unclear.
The present study investigated the clinical significance of the methylation status of the promoter region of the CDH13 gene in serum samples from patients with bladder TCC, and examined the correlation between CDH13 promoter methylation status and clinicopathological parameters.

Patients and methods
PARTICIPANTS AND SAMPLE COLLECTION
Using standard methods, peripheral blood samples were obtained from patients with primary bladder TCC and from healthy donors (controls), who attended the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China, between May 2003 and May 2005; healthy donors were matched to the bladder-cancer cases by age and sex. Serum was isolated from clotted blood by pipette and stored at -80°C until DNA extraction. None of the patients had received any therapy prior to blood sampling. Tumour diagnosis, staging, treatment and follow-up were completed according to international standards. 19 Written informed consent was obtained from each patient and healthy donor. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Third Hospital of Hebei Medical University.
DNA EXTRACTION, BISULPHITE MODIFICATION AND MSP
DNA was extracted from serum samples using a QIAmp ® DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted DNA was treated with bisulphite, to convert unmethylated cytosines to uracils prior to methylation-specific polymerase chain reaction (MSP), using an EpiTect ® Bisulfite Kit (Qiagen, Valencia, CA, USA), following the manufacturer's protocol. The methylation status of the promoter region of the CDH13 gene was examined by MSP, using primers specific for methylated and unmethylated CDH13 sequences, as described previously. 20 -22 Briefly, the primer sequences of CDH13 for the unmethylated reaction were CDH13 (unmethylated sense), 5′-TTGTGGGGTTGTTTTTTGT-3′ and CDH13 (unmethylated antisense), 5′AACTTT TCATTCATACACACA-3′, which amplify a 242-base pair product. The primers for the methylated reaction were CDH13 (methylated sense), 5′-TCGCGGGGTTCGTTT TTCGC-3′ and CDH13 (methylated antisense), 5′-GACGTTTTCATTCATACACGC G-3′, which amplify a 243-base pair product. The polymerase chain reaction amplification of modified DNA samples consisted of one cycle of 95°C for 5 min, followed by 33 cycles of 95°C for 30 s, 60°C for 1 min and 72°C for 1 min for the unmethylated reaction, or 29 cycles of 95°C for 30 s, 70°C for 1 min and 72°C for 1 min for the methylated reaction, followed by a final cycle of 72°C for 5 min. DNA from 5637 (bladder cancer cell line) and SW1417 (colon cancer cell line) were used as positive controls for amplification of unmethylated and methylated CDH13 alleles, respectively. 23, 24 Water blanks were included with each assay as negative controls. The polymerase chain reaction products were visualized on 2% agarose gels stained with ethidium bromide. Samples were scored as methylation-positive when methylated alleles were visualized as bands in the methylated DNA lane, and as methylationnegative when bands were seen only in the unmethylated DNA lane. Results were confirmed by repeating MSP assays for all samples; each MSP was repeated at least three times.
OVERALL SURVIVAL
Patients' overall survival data were collected. Overall survival was defined as the time from the date of diagnosis to the date of death from any cause, or last contact if the patient was still alive. For data analysis, patients were divided into two groups according to their methylation status: the YL Lin, G Sun, XQ Liu et al. CDH13 methylation and bladder TCC CDH13 methylated group or the CDH13 unmethylated group.
STATISTICAL ANALYSES
Statistical evaluation of the data was carried out using the SAS ® statistical package, version 8.0 (SAS Institute, Cary, NC, USA) for Windows ® . The χ 2 -test was used to assess the association between CDH13 methylation status and clinicopathological features. Kaplan-Meier survival analysis and the logrank test were used to assess the difference in overall survival between patients with methylated and unmethylated CDH13. The multivariate Cox proportional hazards model analysis was used to estimate the independent prognostic effect of CDH13 methylation, controlling for the classic risk factors of tumour stage, grade and size at diagnosis. 8, 21, 25 A P-value < 0.05 was considered to be statistically significant.
Results
The methylation status of the CDH13 gene in serum samples from 127 patients with bladder TCC and 41 healthy volunteers was analysed using MSP. CDH13 promoter methylation was detected in 39 (30.7%) patients with bladder TCC, while no methylation of the CDH13 promoter was observed in serum from healthy volunteers.
CDH13 promoter methylation in serum was significantly associated with advanced tumour stage (P < 0.0001), poor tumour differentiation (tumour grade) (P = 0.0141), larger tumour size (P = 0.0451) and tumour recurrence (P = 0.0024) ( Table 1) . No correlation was found between CDH13 
TABLE 1: Clinicopathological parameters for patients with bladder transitional cell carcinoma and their associations with methylation of the promoter region of the CDH13 (H-cadherin; T-cadherin) gene
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promoter methylation and age, sex, tumour number or shape (Table 1) .
Overall survival data were available for all patients. For patients with bladder TCC, the group with methylated CDH13 had a worse outcome than the group with unmethylated CDH13 (P < 0.0001; Fig. 1 ). Multivariate analysis showed that the methylation of the CDH13 promoter in serum was independently associated with poor outcome and had a relative risk of death of 8.034 (95% confidence intervals 3.011, 21.438; P < 0.0001; Table 2 ).
Discussion
Changes in the status of DNA methylation are among the most common molecular alterations in human tumours. Promoter methylation of the human gene is a major mechanism for gene inactivation and can be used as a potential biomarker in human cancers: methylated DNA can be detected in body fluids, including serum, and in tumour tissues. 17,26 -29 The presence of circulating tumour DNA in serum from patients with cancer has been demonstrated previously, and there is a substantial proportion of circulating DNA in cancer patients that derives from tumour cells and results from DNA leakage caused by tumour necrosis or apoptosis. The circulating DNA has a similar methylation status to that found in tumours, therefore methylated DNA in serum may potentially be used as a novel, convenient and non-invasive biomarker for patients with cancer. 21, 25, 29 The methylation status of the CDH13 gene promoter in serum samples from patients with bladder TCC and normal healthy volunteers was systematically investigated in the present study. CDH13 promoter methylation was detected in 39 (30.7%) patients with bladder TCC, but was not observed in the healthy volunteers. This suggests that CDH13 promoter methylation in serum is tumour specific, closely correlated with the malignant behaviour of bladder TCC, and can be used as a potential biomarker in bladder TCC. The analysis of serum CDH13 promoter methylation in relation to clinicopathological features in the present study showed that it was significantly correlated with more malignant tumour behaviour, in patients with bladder TCC. Specifically, compared with other patients, CDH13 promoter methylation was observed more frequently in serum samples from patients with advanced disease stage, high tumour grade and tumours > 3 cm in diameter, which are all risk factors for tumour progression and poor prognosis. 30, 31 This is similar to a previous report demonstrating that methylation of the CDH13 promoter in bladder cancer tissues is closely associated with tumour malignancy. 32 Additionally, recurrence is an important feature of bladder cancer and the high relapse rate is a major factor that influences patient outcome. 30 It has been reported that the loss of CDH13 caused by promoter methylation is an important determinant of the mechanisms involved in the recurrence of several human cancers. 12, 33 Promoter methylation of CDH13 in pre-treatment serum samples occurred more frequently in patients with tumour recurrence during follow-up than in patients without tumour relapse, in the present study. This finding suggests that CDH13 promoter methylation may contribute to the recurrence of bladder TCC and could be used as a potential predictor for bladder TCC recurrence. Taken together, the data indicated that promoter methylation of CDH13 in pre-treatment serum samples is closely associated with malignant behaviours of bladder TCC, suggesting that CDH13 hypermethylation in serum could be used as a potential predictor for the malignancy of bladder TCC.
As bladder cancer is common worldwide, with a high morbidity and mortality, it is critical to identify which patients are at a high risk of death following initial 'curative' treatment at diagnosis. 2, 3, 34, 35 CDH13, a member of the cadherin family, functions as a tumour suppressor, and inactivation of CDH13 caused by promoter methylation is a common finding in human cancers. 12 Additionally, methylated DNA recovered from the serum of patients with various malignancies reflects tumour-specific epigenetic alterations of the tumour. 36 -38 Thus, the investigation of CDH13 promoter methylation as a prognostic parameter in serum samples from patients with various malignancies could be of interest. When overall survival of patients was examined in terms of serum CDH13 methylation status in • Received for publication 9 November 2010 • Accepted subject to revision 10 November 2010 • Revised accepted 21 December 2010 Copyright © 2011 Field House Publishing LLP the present study, it was observed that CDH13 promoter methylation was closely associated with worse prognosis. Multivariate analysis also indicated that CDH13 promoter methylation in serum was an independent predictor of patient outcome. Moreover, the results were similar to previous findings in cervical cancer. 25 These data suggested that CDH13 promoter methylation in pre-therapeutic serum samples may be used as an independent predictor of outcome for patients with bladder TCC. For patients with CDH13 promoter methylation in serum samples, follow-up should be strengthened and effective post-surgical intervention should be performed, to achieve a better prognosis.
In conclusion, in the present study, methylation of the promoter of CDH13 in serum from patients with bladder TCC occurred frequently before treatment and was significantly correlated with advanced disease stage, high-grade tumour, larger tumour size, tumour recurrence and poor prognosis. These results suggest that CDH13 promoter methylation could be used as a useful predictive biomarker in routine clinical practice. CDH13 promoter methylation in serum may be used to identify patients with more aggressive disease, to detect cancer relapse early and to predict patient survival. Moreover, demonstration of CDH13 promoter methylation in serum may be used as a predictive marker for identifying which patients will need more aggressive additional systemic therapy following surgery.
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